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Bipolar disorder, schizophrenia and recurrent major depression are complex psychiatric illnesses with a
substantial, yet unknown genetic component. Linkage of bipolar disorder and recurrent major depression
with markers on chromosome 4p15–p16 has been identiﬁed in a large Scottish family and three smaller
families. Analysis of haplotypes in the four chromosome 4p-linked families, identiﬁed two regions, each
shared by three of the four families, which are also supported by a case-control association study. The
candidate gene phosphatidylinositol 4-kinase type-II beta (PI4K2B) lies within one of these regions. PI4K2B
is a strong functional candidate as it is a member of the phosphatidylinositol pathway, which is targeted
by lithium for therapeutic effect in bipolar disorder. Two approaches were undertaken to test the PI4K2B
candidate gene as a susceptibility factor for psychiatric illness. First, a case-control association study,
using tagging SNPs from the PI4K2B genomic region, in bipolar disorder (n = 368), schizophrenia
(n = 386) and controls (n = 458) showed association with a two-marker haplotype in schizophrenia but
not bipolar disorder (rs10939038 and rs17408391, global P = 0.005, permuted global P = 0.039). Second,
expression studies at the allele-speciﬁc mRNA and protein level using lymphoblastoid cell lines from
members of the large Scottish family, which showed linkage to 4p15–p16 in bipolar disorder and recur-
rent major depression, showed no difference in expression differences between affected and non-affected
family members. There is no evidence to suggest that PI4K2B is contributing to bipolar disorder in this
family but a role for this gene in schizophrenia has not been excluded.
 2009 Elsevier Ltd. Open access under CC BY license.1. Objectives
Genetic evidence for psychiatric illness, including bipolar disor-
der, schizophrenia and related phenotypes to chromosome 4p15–
p16, has been established in linkage, population and affected indi-
vidual studies as detailed previously (Le Hellard et al., 2007). Hap-
lotype analysis of chromosome 4p15–p16 using four families with
linkage to that region, highlighted two areas in the 20 Mb linked
region, where three of the four linkage regions overlap, namely re-
gion B and region D (Le Hellard et al., 2007). These regions have
been supported by association analysis in the Scottish population
(Christoforou et al., 2007). Region D appeared an attractive region
for further study because of the strength of the linkage evidence
from a Welsh family with schizophrenia and schizoaffective disor-
der (LOD 2, (Asherson et al., 1998)) and a large family from the Uni-
ted States of Ashkenazi Jewish origin with major mental illnessY license.
ent of Psychology, 7 George
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lihan).including bipolar disorder and schizophrenia (LOD 3.2, (Detera-
Wadleigh et al., 1999)). Of the 13 known genes in region D (Le Hel-
lard et al., 2007), PI4K2B has the strongest case as a candidate gene
from biological and neuropharmacological evidence. In addition,
the aforementioned association study identiﬁed SNP rs10939038,
which lies in the same linkage disequilibrium (LD) block as PI4K2B,
as a potentially important variant in schizophrenia cases (allele
P = 0.006, odds ratio (OR) = 1.314, 95%CI: 1.08–1.59) (Christoforou
et al., 2007).
PI4K2B is a phosphatidylinositol 4-kinase and a member of the
phosphoinositide (PI) signal transduction pathway. Its primary
function is the phosphorylation of phosphatidylinositol to generate
phosphatidylinositol 4-phosphate (Balla et al., 2002; Wei et al.,
2002). The PI signalling pathway is a target for the mood stabilising
drugs, lithium and sodium valproate (Berridge et al., 1989; Farmer
et al., 2007; Kato, 2007).
This study examined PI4K2B as a possible genetic risk factor in
bipolar disorder or schizophrenia, by two approaches. First, a
case-control association study tested association of additional
markers in the PI4K2B region in 368 cases with bipolar disorder,
386 cases with schizophrenia and 458 controls from the Scottish
L.M. Houlihan et al. / Journal of Psychiatric Research 43 (2009) 1272–1277 1273population. Second, RNA and protein expression analysis of PI4K2B
was conducted with lymphoblastoid cell lines from members of
the large Scottish family, which showed linkage to the chromo-
some 4p15–p16 region (Blackwood et al., 1996).2. Materials and methods
2.1. Case-control association study
2.1.1. Sample
The cohort consisted of DNA from individuals with bipolar dis-
order (368; 160 males and 208 females), schizophrenia (386; 276
males and 110 females) and controls (458; 237 males, 218 females
and three unknown). Details of this sample have been previously
reported (Christoforou et al., 2007). The study was approved by
the Multi-Centre Research Ethics Committee for Scotland. The
sample comprised individuals contacted through the inpatient
and outpatient services of hospitals in South East Scotland. Diagno-
ses according to DSM-IV criteria were based on information from
an interview with the patient using the Schedule for Affective Dis-
orders and Schizophrenia-Life time version (SADS-L) were reached
by consensus between two trained psychiatrists. Controls from the
same region were recruited through the South of Scotland Blood
Transfusion Service and from hospital staff. Control subjects were
drawn from the same population in South East and South Central
Scotland. The majority (>80%) were recruited through the Scottish
National Blood Transfusion service. Although the blood donors
were not screened by interview for personal or family history of
psychiatric illness, donors are only allowed to donate blood if they
are not currently on medication and had no chronic illness. The
remaining controls were recruited from the local population and
from hospital staff. These controls were brieﬂy screened by inter-
view to exclude anyone currently on medication or with a history
of treatment for psychiatric illness.
2.1.2. SNP Selection
SNP genotype data from 30 CEPH trios, 100 kb upstream and
downstream of the PI4K2B genomic region (24,745,440–
24,986,687 bp, NCBI build 35) from HapMap Phase II (January
2006) (http://www.hapmap.org) was uploaded to Haploview ver-
sion 3.2 (Barrett et al., 2005). Tagging SNPs were selected as previ-
ously described (Christoforou et al., 2007), with one exception that
haplotypes were tagged down to the 5% level for ﬁner coverage of
the region.
2.1.3. Genotyping
Genotyping was performed with pre-designed Taqman assays
on demand or assays by design from Applied Biosystems using
the ABI PRISM 7900HT sequence detection system. The seven SNPs
were successfully genotyped with an average locus success rate of
95% (range: 89–99%) in a total number of 1212 individuals (93%
sample success rate). Further descriptive information on the SNPs
is available in Supplementary Table 1.
2.1.4. Association analysis
Power calculations showed this study would reach a signiﬁ-
cance level a = 0.01, with >93% power for association of an allele
that shows a heterozygote relative risk (multiplicative model) of
two, assuming a risk allele frequency of 10% and a lifetime preva-
lence of 1% in 368 individuals (number of bipolar disorder cases)
(Purcell et al., 2003). The power available in our study decreases
when more modest relative risks are used (relative risk 1.2–1.5
estimates the available power 18–67% at a = 0.01). The standard
v2 test of independence was used to examine deviations of the
11 SNPs from Hardy–Weinberg equilibrium (HWE) in the controlsample (all HWE P-valuesP 0.001 as Haploview default (Wiggin-
ton and Abecasis, 2005); minimum HWE P = 0.04). Single-marker
analysis was performed using in the v2 test of independence
(Dudbridge, 2003). Haplotype analysis was performed separately
on bipolar disorder and schizophrenia cases with CoCaphase 2.4
(Dudbridge, 2003), using a sliding-windows approach to test all
haplotypes of two marker length. Rare haplotypes with a fre-
quency 6 0.05 in both cases and controls were clumped together.
Permutation analysis was also performed using CoCaphase.
2.2. Expression analysis
2.2.1. DNA samples
Lymphoblastoid cell lines from members of the large Scottish
family were grown under standardised conditions, following stan-
dard protocols. All cell lines were subjected to the same cell culture
and experimental conditions. Genomic DNA (gDNA) and RNA were
prepared by the DNeasy Tissue Kit (Qiagen) and RNeasy Mini Kit
(Qiagen) respectively. mRNA was reverse transcribed to cDNA with
First Strand cDNA Kit (Roche) using random primers. ‘‘Quant-iT
PicoGreen dsDNA Reagent and Kit” (Molecular Probes) was used
to quantify DNA.
2.2.2. Allelic imbalance assay
rs313548 and rs313567 were available as pre-designed Taq-
man SNP genotyping assays (c_764549, c_764538, respectively)
while rs6834255 was a custom designed Taqman SNP genotyp-
ing Assay (ABI). A standard curve of dilutions from homozygous
lymphoblastoid cell line samples was prepared to evaluate the
contribution of each allele in the heterozygote samples; genomic
DNA prepared from two homozygote samples (5 ng/ll), as previ-
ously published (Pastinen et al., 2004). Ten microgram of mixed
gDNA was assessed in a total volume of 5 ll, 2 ll gDNA, 0.25 ll
Taqman SNP Genotyping Assay, 2.5 ll Taqman Universal PCR
Master Mix, 0.25 ll dH2O. Each homozygote mix was assayed
in quadruplicate. A standard curve (linear regression line) was
established for the LOG of the ﬂuorescent intensity ratio
(FAMTM/VIC) versus the log of the allele ratio, i.e. the LOG2 ratio
of the dilution of each homozygote (90:10 = LOG2 Ratio is 3.147),
as previously published (Lo et al., 2003). For the heterozygote
DNA samples, 4 ng cDNA or 10 ng gDNA was ampliﬁed; 2 ll
cDNA (2 ng/ll) or 2 ll gDNA (5 ng/ll), 0.25 ll Taqman SNP
Genotyping Assay, 2.5 ll Taqman Universal PCR Master Mix,
0.25 ll dH2O. Each sample was prepared in quadruplicate and
each assay was performed in triplicate from the same RNA prep-
aration. The standard assay was performed in the ABI PRISM
7900HT sequence detection system (Applied Biosystems). From
the endpoint read, the ratio of the ﬂuorescence reading from
the FAMTM reporter dye and VIC reporter dye was calculated.
cDNA values were calculated by the cDNA/gDNA ratio from the
mean value of DNA from the same individual.
2.2.3. Quantitative immunoblotting
The Western blotting procedure was performed on 5 lg protein
lysates using NuPAGE Electrophoresis System, as per manufac-
turer’s instructions with 17-well 4-12% Bis–Tris gels. Densitometry
analysis was performed using ImageJ v 1.37 (Abramoff et al., 2004)
to quantify the immunoreactive protein in each lane.3. Results
3.1. Case-control association study
Fig. 1 shows sliding-window analysis of two-SNP haplotypes
where two haplotypes emerged as signiﬁcant at the global level
1274 L.M. Houlihan et al. / Journal of Psychiatric Research 43 (2009) 1272–1277in the schizophrenia sample: rs17408391–rs10939038 (global
P = 0.005, permuted global P = 0.039, SE:0.006) and rs10939038–
rs3756207 (global P = 0.01, permuted global P > 0.05). Supplemen-
tary Table 2 shows the signiﬁcant individual haplotype structures
and corresponding P-values for these global haplotypes. Haplotype
rs17408391–rs10939038 spans from LD block 1 to LD block 2,
while haplotype rs10939038–rs3756207 falls within LD block 2
as illustrated in Fig. 1. Analysis at the single-marker level showed
the only signiﬁcant single-marker association less than the nomi-
nal signiﬁcant level (P = 0.05) was rs10939038 in the schizophrenia
cases (P = 0.006), which was previously reported (Christoforou
et al., 2007) (data not shown). This association withstood the
gene-wide permutation testing (1000 simulations) performed for
this study (permuted P = 0.015, standard error (SE) = 0.0038). No
association was detected in either bipolar disorder or schizophre-
nia at the single-marker level (all single marker P-values > 0.05)
for the seven additional SNPs, which were selected to increase cov-
erage of the PI4K2B region.
3.2. Expression studies
PI4K2B expression was measured at the RNA and protein level
in lymphoblastoid cell lines from members of a large Scottish fam-
ily. Certain members of the family have a deﬁned haplotype on
chromosome 4p15–p16, referred to as ‘‘the linked haplotype” that
segregates with the majority of cases of bipolar disorder and recur-
rent major depression, as described previously (Le Hellard et al.,
2007). RNA expression of PI4K2B was assessed in lymphoblastoid
cell lines by allele-speciﬁc quantitative RT-PCR using three SNPs
by Taqman technology comparing relatives with and without the
‘‘linked haplotype”. Estimation of allelic imbalance from standard
curves was performed as previously described (Pastinen et al.,
2004). Based on the standard curves, we found that deviation from
equal expression could reliably be detected from both alleles
(50:50) at a 80:20 allele ratio at rs313567, a 90:10 allele ratio at
rs313548 and a 70:30 allele ratio at rs6834255, respectively. The0.001
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Fig. 1. Distribution of global haplotype P-values from two-marker sliding window haplo
base pairs (bp) according to the human genome map of UCSC May 2004, NCBI build 35. Th
grey and schizophrenia in black. The nominal signiﬁcance threshold is indicated with a
map of the region was deﬁned by solid spine of LD (D’ > 0.8) using HapMap CEU trios do
PI4K2B and SLA/LP are denoted with black arrows. The markers underlined are the follo
genotyped previously (n = 4) (Christoforou et al., 2007). The P-value for the ﬁrst two mark
be seen.allelic imbalances observed for the heterozygote cDNA samples
did not reach the detection threshold (data not shown). To detect
a more sensitive difference, gDNA measurements from heterozy-
gotes were incorporated, which represented equal expression from
each allele, as a control, as previously performed (Bakker et al.,
2007). Fig. 2 shows the allelic expression at rs313548 between
linked haplotype carriers (n = 13) and controls (n = 10). There
was no difference in allele expression of rs313548 between indi-
viduals with the PI4K2B linked haplotype and those who do not
have the haplotype (t-test P = 0.28). Furthermore, there was no dif-
ference in allele expression between individuals with the PI4K2B
linked haplotype and those who do not have the haplotype for
rs6834255 (t-test P = 0.98) and rs313567 (t-test P = 0.36) (data
not shown). PI4K2B protein expression was detected in lympho-
blastoid cell lines derived from the large Scottish family: Twelve
samples with a ‘‘linked haplotype” and a psychiatric diagnosis
[bipolar disorder (n = 4), recurrent major depression (n = 4), no
symptoms (n = 4)] and founder individuals as controls (n = 4).
Fig. 3 shows no evidence for a PI4K2B protein expression difference
between linked haplotype carriers and controls in ﬁve replicate
western blot experiments (t-test P > 0.1).4. Discussion
PI4K2B was a worthy candidate gene for bipolar disorder in
many respects. Positional evidence from linkage and association
analyses have implicated this genomic region on chromosome
4p15–p16. Genetic evidence has also suggested other members
of the phosphoinositide signalling pathway as susceptibility fac-
tors for bipolar disorder, schizophrenia and recurrent major
depression (Kato, 2007) and components of the phosphoinositide
pathway are inhibited by lithium, a therapeutic agent in bipolar
disorder (Berridge et al., 1989). Indeed a recent consortium has
been initiated to investigate all genes involved in the lithium path-
way as candidate genes for psychiatric illness (Schulze et al., in48
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Fig. 2. PI4K2B allelic expression at rs313548 between linked haplotype carriers and controls. The heterozygote lymphoblastoid cell line samples are shown on the x-axis. The
cDNA/gDNA ratio for each sample is shown on the y-axis. This ratio is the mean of three assays, each with four replicates, calculated as intensity FAM/intensity VIC. The error
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Fig. 3. No evidence for a PI4K2B protein expression difference between linked haplotype carriers and controls. PI4K2B protein expression (a) was detected at 55 kDa in 5lg
protein preparations from lymphoblastoid cell lines (Minogue et al., 2001). This is an example Western blot of ﬁve Western blots performed. Detection of a-tubulin, b-actin
and GAPDH at 50, 42 and 40 kDa, respectively were used as a loading control. Protein expression levels were measured by densitometry (Abramoff et al., 2004). PI4K2B
expression level was normalised against the mean expression level from the protein loading controls. The box and whiskers plot (b) shows the ﬁve-number summary of ﬁve
replicate gels; lower quartile, median, upper quartile, and largest observation. The dark grey bars represent individuals with a linked haplotype and light grey bars represent
married-in control individuals.
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basis of psychiatric illness research by adopting a candidate gene
study with two approaches; (i) an association study in 368 bipolar
disorder, 386 schizophrenia and 458 Scottish participants and (ii)
an expression study in lymphoblastoid cell lines from bipolar dis-order and recurrent major depression members of a large Scottish
family.
This study identiﬁed association between a haplotype in PI4K2B,
which withstood gene-wide permutation testing, and schizophre-
nia, but not bipolar disorder. This improved haplotype association,
1276 L.M. Houlihan et al. / Journal of Psychiatric Research 43 (2009) 1272–1277relative to the original single-marker ﬁnding, may better tag the
actual susceptibility variant and thus narrow the target region. If
replicated, the association results may reﬂect association with
any feature within the large >240 kb genomic region investigated,
in particular PI4K2B or a neighbouring gene SLA/LP. Previous eval-
uation of population structure showed no evidence of population
stratiﬁcation in the control group, suggesting that this is unlikely
to be the cause of any spurious association due to population strat-
iﬁcation (Christoforou et al., 2007).
This study of PI4K2B expression levels has shown no difference
in lymphoblastoid cell line samples from bipolar disorder family
members with the ‘‘linked haplotype” and those without. This
was demonstrated at the allele-speciﬁc level by Taqman assays
and at the protein level by quantitative immunoblotting tech-
niques. The advantage of the Taqman method was the sensitivity
obtained by comparing the linked haplotype to a series of different
control alleles within the one family, using a well-validated meth-
od (Bakker et al., 2007; Pastinen et al., 2004). This method could re-
veal the presence of cis-acting regulatory variants, which may
contribute to susceptibility for bipolar disorder. Cis-acting varia-
tion has been reported to account for 25–35% of inter-individual
differences in gene expression throughout the human genome
(Pastinen and Hudson, 2004). Three PI4K2B SNPs were used to
measure gene expression levels, one of which was an intronic
SNP to measure heteronuclear RNA as previously described
(Pastinen et al., 2004). Initially, standard curves of homozygote
gDNA dilutions were created, to look for a deviation from the
expected 1:1 allelic ratio in cDNA. Despite optimisation attempts,
the standard curves did not achieve the required sensitivity to
detect small differences. However, the standard curves were useful
to show that a gross deviation in allele-speciﬁc expression was not
present. A second method, which compared expression in cDNA to
that seen in gDNA from heterozygous samples, proved more
sensitive. Indeed, in the future it may be useful to investigate
lymphoblastoid cell lines from schizophrenia patients for PI4K2B
expression differences due to the above association study evidence.
The limitations of this expression study are the sensitivity of the
technical procedures, the reduced power from the limited number
of heterozygote family members with viable lymphoblastoid cell
lines available and whether lymphoblastoid cell lines effectively
model pathogenic processes in the brain (Gladkevich et al., 2004;
Tsuang et al., 2005). Studies have shown that whole blood does
share signiﬁcant gene expression similarities with multiple central
nervous system tissues (Sullivan et al., 2006). There is also evi-
dence to suggest that gene expression proﬁles and functional ef-
fects in blood lymphocytes do correlate with psychiatric illness
(Gladkevich et al., 2004; Iwamoto et al., 2004; Marazziti et al.,
2006; Tsuang et al., 2005; Vawter et al., 2004).
This study showed that there was no direct evidence for a role
of PI4K2B in susceptibility to bipolar disorder from expression
studies in lymphoblastoid cell lines. Nevertheless, this candidate
gene still merits further investigation to assess its potential role
in psychiatric illness, because of the signiﬁcant case-control associ-
ation study result that withstood permutation testing.Conﬂict of interest
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